Document is current
Any future updates will be listed below
-
Authors
Croon, Philip M.
van Vugt, Marion
Allaart, Cornelis P.
Ruijsink, Bram
Elliott, Perry M.
Asselbergs, Folkert W.
Khera, Rohan
Bezzina, Connie R.
Winter, Michiel
Schmidt, A. Floriaan
-
Funding
Funding for this research was provided by:
University of Amsterdam Research Priority Agenda Program AI for Health Decision-Making
Amsterdam Cardiovascular Sciences
- License Information
-
More Information
Article History
Received: 7 December 2024
Accepted: 17 June 2025
First Online: 15 July 2025
Declarations
:
: Ethics approval for the UKB study was obtained from the North West Centre for Research Ethics Committee (11/NW/0382) and all participants provided informed consent.
: Consent for publication is not required, because no details on individuals are reported within the manuscript.
: AFS has received funding from New Amsterdam Pharma for unrelated projects. PMC is founder, CEO and shareholder of DGTL Health B.V. FWA is supported by UCL Hospitals NIHR Biomedical Research Centre. RK is an Associate Editor of JAMA. He receives support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under awards R01HL167858 and K23HL153775), the Doris Duke Charitable Foundation (under award 2022060), and the Blavatnik Family Foundation. He also receives research support, through Yale, from Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of U.S. Pending Patent Applications 63/562,335, 63/177,117, 63/428,569, 63/346,610, 63/484,426, 63/508,315, and 63/606,203. He is a co-founder of Ensight-AI, Inc. and Evidence2Health, health platforms to improve cardiovascular diagnosis and evidence-based cardiovascular care.
